Locations:
Search IconSearch
February 22, 2021/Cancer

Racial Disparities and Young-Onset Colorectal Cancer Outcomes

A negative impact despite income or education status

21-DDI-2053805-Racial-Disparities-Young-onset-Colorectal-Cancer

Black patients with young-onset colorectal cancer (CRC) were more likely to present with late-stage disease and have worse outcomes regardless of insurance type, income or education level, according to a study of over 1 million patients presented at the 2021 American Society of Clinical Oncology Gastrointestinal Cancers Symposium.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

“Many studies have shown that Black patients with colorectal cancer unfortunately have worse outcomes, with lower socioeconomic status being the biggest factor. Our study was unique in demonstrating that younger Black patients with high socioeconomic status still experience worse outcomes,” says Suneel Kamath, MD, a colorectal cancer specialist at Cleveland Clinic Cancer Center and lead author of the study.

Young-onset colorectal cancer

The overall incidence of CRC is rising in people under the age of 50, and Black and Hispanic patients have felt this disease burden more severely. This study included 1,061,204 patients with CRC from the National Cancer Database from 2004 to 2015. Just over ten percent of the patients were under age 50. Researchers tracked and compared differences in demographics, socioeconomic factors and disease and treatment characteristics in older (> 50 years of age) versus younger (50 years of age or less) patients.

Younger patients were more likely to be Black (15.1% vs. 11.3%) or Hispanic (8.6% vs. 4.6%) and to be diagnosed with stage 4 disease (24.9% vs. 17.0%) than older patients (P < 0.0001 for all). Black patients had the lowest median overall survival (OS) (58.3 months) when compared with White (67 months), Hispanic (91.6 months) and Asian (104.9 months) patients (P < 0.0001).

Researchers also analyzed patients by insurance level and found that Black early-onset CRC patients with private insurance had worse OS than White patients at every income and education level. The same was not true for Asian and Hispanic patients, or for older patients with CRC.

Advertisement

“Now that we have the data to show that patients in the Black community have been hit harder by this increase in early onset colorectal cancer, we can begin the work of addressing the environmental issues and health disparities behind it,” says David Liska, MD, Director of the Sanford R. Weiss, MD, Center for Hereditary Colorectal Neoplasia at Cleveland Clinic’s Digestive Disease & Surgery Institute and coauthor of the study.

Many factors are likely at play. “Our future work will use metabolomics to understand how differences in the interactions between our cellular processes and environmental exposures like diet could lead to higher risk for CRC,” says Dr. Kamath. The gut microbiome could also impact CRC risk and is another active area of research at Cleveland Clinic. “We also plan to investigate different insurance plans to see if reduced coverage for important things such as screening colonoscopies or specialist referrals might contribute to this study’s results,” he adds.

New Center for Young-Onset Colorectal Cancer

While a cancer diagnosis at any age calls for expert treatment, young patients with colorectal cancer often have diagnostic and treatment considerations that are specific to their early age of onset.

To meet this challenge, Cleveland Clinic established the Center for Young-Onset Colorectal Cancer with the aim of providing young colorectal cancer patients with personalized, comprehensive and coordinated world-class care. The center brings together caregivers in surgery, oncology, radiation therapy, genetics, gastroenterology, fertility, psychology and lifestyle medicine. Patients can also benefit from genetic testing and the expertise of the Weiss Center for Hereditary Colorectal Neoplasia.

Advertisement

Researchers with the center are exploring contributors to the rise in young-onset CRC, including health disparities, as well as developing screening recommendations and novel treatments for this population. To refer a patient to the Center for Young-Onset Colorectal Cancer, call 216.444.6470.

Advertisement

Related Articles

Doctors working on MGUS screening study
March 18, 2024/Cancer/Research
Pilot Study Aims for Early Identification of Multiple Myeloma Precursor Among Black Patients

First-of-its-kind research investigates the viability of standard screening to reduce the burden of late-stage cancer diagnoses

Hematologist at Cleveland Clinic
March 14, 2024/Cancer/Blood Cancers
Advances in Mantle Cell Lymphoma Treatment (Podcast)

Global R&D efforts expanding first-line and relapse therapy options for patients

Physician with patient
March 6, 2024/Cancer/Research
Targeting Uncontrolled Erythrocytosis in Polycythemia Vera with Rusfertide

Study demonstrates ability to reduce patients’ reliance on phlebotomies to stabilize hematocrit levels

Dr. Jagadeesh at Cleveland Clinic
February 28, 2024/Cancer/Blood Cancers
Treating Patient with Systemic T-Cell Lymphoma and Graft-Versus-Host Disease

A case study on the value of access to novel therapies through clinical trials

Doctor measuring patient's waist size
February 26, 2024/Cancer/Research
Impact of Obesity on GVHD & Transplant Outcomes in Hematologic Malignancies

Findings highlight an association between obesity and an increased incidence of moderate-severe disease

Physician with patient
February 21, 2024/Cancer/Research
Strategies for Improving Clinical Trial Equity

Cleveland Clinic Cancer Institute takes multi-faceted approach to increasing clinical trial access 23456

How antibody drug conjugates work
February 13, 2024/Cancer/Research
Real-World Use of Trastuzumab Deruxtecan

Key learnings from DESTINY trials

CQD-4445459-rotz-650&#215;450
February 7, 2024/Cancer
Advances in Bone Marrow Transplant Have Improved Outcomes in Fanconi Anemia

Overall survival in patients treated since 2008 is nearly 20% higher than in earlier patients

Ad